AD35 VACCINATION · Vaccination based on the recombinant ad35 adenoviral vector and ad5fib35 chimeric vector.

Линиите свързват координатора с партньорите.

Накратко на български

Цел на проекта

Crucells research training will involve the investigation of the possibilities to develop recombinant Ad35 as a vaccine delivery vehicle. The Vaccine Research Department will execute the following projects: a) Generation of a vector system and adenovirus packaging cell lines to produce high titered stocks of replication deficient Ad35 virus and subsequent in viva testing of efficacy and toxicity of these vectors, and b) investigation of the efficacy and safety profile of Ad5fib35 vectors in in vivo models (rodents, non-human primates). Although recombinant Ad35 is regarded as the vector of choice for vaccination it will be necessary to further investigate the Ad5fib35 chimeric vector because extensive knowledge, obtained in the past years in pre-clinical and clinical studies with Ad5-based vectors, is lacing for Ad35-based vectors, The advantage of Ad5Fib35 is that these vector can be efficiently produced at pharmaceutical scale with Crucells existing production technology. Safety, toxid, and efficacy studies with Ad5Fib35 will need to be executed to generate valuable information concerning the use of Ad35 based vectors in different vaccination programs. The general aim of this research project will be to develop antigens resulting in protection upon infection (prophylactic vaccination) or even eradication of diseased cells (therapeutic vaccination).

Оригинален текст от CORDIS (на английски).

Участници

• CRUCELL HOLLAND B.V. · LEIDENКоординаторНидерландия

Връзки

• Виж в CORDIS